A Phase II Trial Expansion Cohort of the PARP Inhibitor Veliparib (ABT888) and Temozolomide in BRCA1/2 Associated Metastatic Breast Cancer.

被引：14
|
作者：
Isakoff, S. J. [1 ]
Overmoyer, B. [1 ]
Tung, N. M. [1 ]
Gelman, R. S. [1 ]
Habin, K. [1 ]
Qian, J. [1 ]
Giranda, V. [1 ]
Shepherd, S. [1 ]
Garber, J. E. [1 ]
Ellisen, L. W. [1 ]
Winer, E. P. [1 ]
Goss, P. E. [1 ]
机构：
[1] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
来源：
CANCER RESEARCH | 2011年 / 71卷
关键词：
D O I：
10.1158/0008-5472.SABCS11-P3-16-05
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3-16-05
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer.
    Isakoff, S. J.
    Overmoyer, B.
    Tung, N. M.
    Gelman, R. S.
    Giranda, V. L.
    Bernhard, K. M.
    Habin, K. R.
    Ellisen, L. W.
    Winer, E. P.
    Goss, P. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [2] Phase II trial of veliparib and temozolomide in metastatic breast cancer patients with and without BRCA1/2 mutations
    Jing Xu
    Tanya E. Keenan
    Beth Overmoyer
    Nadine M. Tung
    Rebecca S. Gelman
    Karleen Habin
    Judy E. Garber
    Leif W. Ellisen
    Eric P. Winer
    Paul E. Goss
    Beow Y. Yeap
    Bruce A. Chabner
    Steven J. Isakoff
    Breast Cancer Research and Treatment, 2021, 189 : 641 - 651
  • [3] Phase II trial of veliparib and temozolomide in metastatic breast cancer patients with and without BRCA1/2 mutations
    Xu, Jing
    Keenan, Tanya E.
    Overmoyer, Beth
    Tung, Nadine M.
    Gelman, Rebecca S.
    Habin, Karleen
    Garber, Judy E.
    Ellisen, Leif W.
    Winer, Eric P.
    Goss, Paul E.
    Yeap, Beow Y.
    Chabner, Bruce A.
    Isakoff, Steven J.
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 189 (03) : 641 - 651
  • [4] Phase II trial of a PARP inhibitor in somatic BRCA mutant metastatic breast cancer.
    Vidula, Neelima
    Horick, Nora K.
    Blouch, Erica
    Rivera, Amalia
    Basile, Erin
    Fax, Ruth
    Ellisen, Leif W.
    Rugo, Hope S.
    Bardia, Aditya
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [5] Combination of the PARP inhibitor veliparib (ABT888) with irinotecan in patients with triple negative breast cancer: Preliminary activity and signature of response
    LoRusso, Patricia M.
    Tolaney, Sara M.
    Wong, Shukmei
    Parchment, Ralph E.
    Kinders, Robert J.
    Wang, Lihua
    Aldrich, Jessica
    Chen, Alice
    Durecki, Diane
    Boerner, Scott A.
    Guthrie, Tina
    Bowditch, Adam
    Heilbrun, Lance K.
    Pilat, Mary Jo
    Craig, David
    Cai, Dongpo
    Bell, Tracy
    Carpten, John
    Shapiro, Geoffrey
    CANCER RESEARCH, 2015, 75
  • [6] Phase II study of talazoparib, a PARP inhibitor, in somatic BRCA1/2 mutant metastatic breast cancer
    Vidula, Neelima
    Horick, Nora
    Basile, Erin
    Blouch, Erica
    Ellisen, Leif W.
    Rugo, Hope S.
    Bardia, Aditya
    CANCER RESEARCH, 2021, 81 (04)
  • [7] Phase II study of a PARP inhibitor in somatic BRCA1/2 mutant metastatic breast cancer (MBC)
    Vidula, Neelima
    Damodaran, Senthil
    Bhave, Manali A.
    Rugo, Hope S.
    Blouch, Erica
    Ruffle-Deignan, Nathan Royce
    Shah, Ami N.
    Cristofanilli, Massimo
    Abramson, Vandana G.
    Sparano, Joseph A.
    Ostrer, Harry
    Horick, Nora K.
    Bardia, Aditya
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [8] A phase II study of the PARP inhibitor ABT-888 plus temozolomide in patients with heavily pretreated, metastatic colorectal cancer
    Pishvaian, M. J.
    Slack, R.
    Witkiewicz, A.
    He, A. R.
    Hwang, J. J.
    Hankin, A.
    Dorsch-Vogel, K.
    Kuda, D.
    McAndrew, T.
    Weiner, L. M.
    Marshall, J.
    Brody, J. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [9] Phase I Study of PARP Inhibitor ABT-888 (Veliparib) in Combination with Cisplatin and Vinorelbine for Patients with Advanced Triple Negative Breast Cancer and/or BRCA-Mutation Associated Breast Cancer
    Rodler, E. T.
    Specht, J. M.
    Gadi, V. K.
    Kurland, B. F.
    Griffin, M. J.
    Hammond, J. J.
    Gralow, J. R.
    CANCER RESEARCH, 2011, 71
  • [10] ABT-888 (veliparib) in combination with carboplatin in patients with stage IV BRCA-associated breast cancer. A California Cancer Consortium Trial.
    Somlo, George
    Sparano, Joseph A.
    Cigler, Tessa
    Fleming, Gini F.
    Luu, Thehang H.
    Hurria, Arti
    Mortimer, Joanne E.
    Frankel, Paul Henry
    Chew, Helen K.
    Nanda, Rita
    Ma, Cynthia X.
    Chen, Alice P.
    Garcia, Agustin
    Vahdat, Linda T.
    Gandara, David R.
    Weitzel, Jeffrey N.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345